225Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy: Pilot Experience From a Prospective Registry.

Florian RosarCaroline BurgardLuna Vanessa RohloffArne BlickleMark BartholomäStephan MausSven PettoAndrea Schaefer-Schuler Samer Ezziddin

Published in: Clinical nuclear medicine (2024)

225Ac-PSMA-617 augmentation in high-risk mCRPC undergoing 177Lu-PSMA-617 RLT appears to be an effective treatment option with a favorable safety profile. The pretherapeutic values of alkaline phosphatase, lactate dehydrogenase, the Eastern European Oncology Group Performance Score, and the presence of visceral metastases may be appropriate biomarkers predicting survival outcome of this treatment regimen.

Keyphrases

pet ct
pet imaging
clinical trial
soft tissue
mesenchymal stem cells
combination therapy
replacement therapy
skeletal muscle
cell therapy